Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer

Huang, Daniel Q.; Singal, Amit G.; Kono, Yuko; Tan, Darren Jun Hao; El–Serag, Hashem B.; Loomba, Rohit

doi:10.1016/j.cmet.2022.05.003

Cited by 284 publications

(187 citation statements)

References 42 publications

Supporting

Mentioning

186

Contrasting

Unclassified

Order By: Relevance

“…NAFL/NASH is predictive of mortality for both males and females [ 26 ]; obesity increases incidence, tumor size, and multiplicity in both female and male mice [ 27 ]. Furthermore, recent findings demonstrate that the prevalence of NASH is no longer dimorphic by sex [ 28 ] and that NASH is the fastest growing cause of HCC, having increased by ~40% from 2010 to 2019 [ 29 ]. HCC in non-cirrhotic livers typically present at more advanced stages, likely due to lack of routine surveillance which is recommended for people with cirrhosis.…”

Section: Epidemiology Of Hccmentioning

confidence: 99%

Obesity Management in the Primary Prevention of Hepatocellular Carcinoma

Zunica

Heintz

Axelrod

et al. 2022

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most frequent primary hepatic malignancy and a leading cause of cancer-related death globally. HCC is associated with an indolent clinical presentation, resulting in frequent advanced stage diagnoses where surgical resection or transplant therapies are not an option and medical therapies are largely ineffective at improving survival. As such, there is a critical need to identify and enhance primary prevention strategies to mitigate HCC-related morbidity and mortality. Obesity is an independent risk factor for the onset and progression of HCC. Furthermore, obesity is a leading cause of nonalcoholic steatohepatitis (NASH), the fasting growing etiological factor of HCC. Herein, we review evolving clinical and mechanistic associations between obesity and hepatocarcinogenesis with an emphasis on the therapeutic efficacy of prevailing lifestyle/behavioral, medical, and surgical treatment strategies for weight reduction and NASH reversal.

show abstract

Section: Epidemiology Of Hccmentioning

confidence: 99%

Obesity Management in the Primary Prevention of Hepatocellular Carcinoma

Zunica

Heintz

Axelrod

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…NAFLD encompasses non-alcoholic fatty liver (NAFL), the benign, non-progressive form, and non-alcoholic steatohepatitis (NASH), the progressive, inflammatory form that can progress to advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [3][4][5][6][7][8] . With the…”

Section: Introductionmentioning

confidence: 99%

Shared Mechanisms between Cardiovascular Disease and NAFLD

et al. 2022

Self Cite

View full text Add to dashboard Cite

The burden of non-alcoholic fatty liver disease (NAFLD) is rising globally. Cardiovascular disease is the leading cause of death in patients with NAFLD. Nearly half of individuals with NAFLD have coronary heart disease, and more than a third have carotid artery atherosclerosis. Individuals with NAFLD are at substantially higher risk of fatal and non-fatal cardiovascular events. NAFLD and cardiovascular disease share multiple common disease mechanisms, such as systemic inflammation, insulin resistance, genetic risk variants and gut microbial dysbiosis. In this Review, we discuss the epidemiology of cardiovascular disease in NAFLD, and highlight common risk factors. In addition, we examine recent advances evaluating the shared disease mechanisms between NAFLD and cardiovascular disease. In conclusion, multidisciplinary collaborations are required to further our understanding of the complex relationship between NAFLD and cardiovascular disease and potentially identify therapeutic targets.

show abstract

“…NAFLD represents a spectrum of liver diseases ranging from simple steatosis (lipid accumulation in the liver) to non-alcoholic steatohepatitis (NASH) and NASH-related cirrhosis, which can eventually lead to the development of hepatocellular carcinoma (HCC). With the current lack of effective treatment options, NASH was predicted to become the main cause of liver transplantation by 2030 [ 2 ] and indeed just recently NASH was determined to be the fastest growing cause of age-adjusted liver cancer deaths globally [ 3 ]. Hepatic inflammation is proposed to be one of the key forces driving the progression from steatosis to NASH and cirrhosis, and interfering with inflammatory pathways has had some success both in pre-clinical and clinical studies [ 4 , 5 ].…”

mentioning

confidence: 99%

Modulating hepatic macrophages with annexin A1 in non-alcoholic steatohepatitis

Ponti

Scott

2022

Clinical Science

View full text Add to dashboard Cite

Non-alcoholic steatohepatitis (NASH) and associated end-stage liver disease is a growing cause of concern throughout the Western world. It constitutes a significant clinical burden for which therapeutic approaches are very limited. Over the last years, considerable attention has therefore been paid to identifying potential therapeutic strategies to reduce this burden. Annexin A1 (AnxA1), a calcium-phospholipid binding protein, has been proposed to be a negative regulator of inflammation in the context of NASH. In a recent publication, Gadipudi, Ramavath, Provera et al. investigated the therapeutic potential of Annexin A1 treatment in preventing the progression of NASH. They demonstrate that treatment of mice with NASH with recombinant human AnxA1 can reduce inflammation and fibrosis without affecting steatosis or metabolic syndrome. This was proposed to be achieved through the modulation of the macrophage populations present in the liver. Here, we discuss the main findings of this work and raise some outstanding questions regarding the possible mechanisms involved and the functions of distinct macrophage populations in NASH.

show abstract

Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer

Cited by 284 publications

References 42 publications

Obesity Management in the Primary Prevention of Hepatocellular Carcinoma

Obesity Management in the Primary Prevention of Hepatocellular Carcinoma

Shared Mechanisms between Cardiovascular Disease and NAFLD

Modulating hepatic macrophages with annexin A1 in non-alcoholic steatohepatitis

Contact Info

Product

Resources

About